Main Article Content
seasonal allergic rhinitis, children, quality of life, symptoms, cetirizine.
Background and aim Seasonal allergic rhinitis (SAR) is a common disease in childhood that is characterized by bothersome symptoms and impaired quality of life (QoL). As histamine is the pivotal pathogenic mediator in SAR, antihistamines are the first-line option in the treatment. Cetirizine is a well-known effective antihistamine. This real-life pilot study aimed to investigate the effectiveness of a 4-week continuous cetirizine treatment in a group of Italian children with SAR.
Methods Total symptom score (TSS) and the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) were assessed at baseline and the end of the treatment.
Results Cetirizine significantly improved QoL (in all domains) and symptom severity (p<0.001 for both).
Conclusions The present preliminary study showed that a 4-week cetirizine treatment was able to improve QoL significantly. Cetirizine treatment also significantly reduced symptom severity in Italian children with SAR and was safe.
2. Wen T, Rothenberg ME. Cell-by-cell Deciphering of T Cells in Allergic Inflammation. J Allergy Clin Immunol 2019;144:1143-8
3. Ciprandi G, Cirillo I, Klersy C, Marseglia GL, Caimmi D, Vizzaccaro A Nasal obstruction is the key symptom in hay fever patients. Otolaryngol Head Neck Surg. 2005;133:429-35
4. Fein MN, Fischer DA, O’Keefe AW, Sussman GL. CSACI Position Statement: Newer Generation H 1-antihistamines Are Safer Than First-Generation H 1-antihistamines and Should Be the First-Line Antihistamines for the Treatment of Allergic Rhinitis and Urticaria. Allergy Asthma Clin Immunol 2019;15:61
5. Ciprandi, G, Klersy C, Cirillo I, Marseglia GL. Quality of Life in Allergic Rhinitis: relationship with clinical, immunological, and functional aspects. Clin Exp Allergy 2007;37:1528-35.
6. Ciprandi G, Cirillo I, Vizzaccaro A, Milanese M, Tosca MA. Nasal obstruction in patients with seasonal allergic rhinitis: relationships between allergic inflammation and nasal airflow. Intern Arch Allergy Immunol 2004;134:34-40
7. Cirillo I, Marseglia GL, Klersy C, Ciprandi G. Allergic patients have more numerous and prolonged respiratory infections than nonallergic subjects Allergy 2007;62:1087-90
8. Corsico A, Leonardi S, Licari A, Marseglia GL, Miraglia del Giudice M, Peroni DG, et al. Focus on the cetirizine use in clinical practice: a reappraisal 30 years later. Multidisciplinary Respiratory Medicine 2019;14:40
9. Ciprandi G, Tosca M. Long-term cetirizine treatment reduces allergic symptoms and drug prescriptions in children with mite allergy. Ann Allergy Asthma Immunol 2001;87:222-6
10. Nayak AS, Berger WE, LaForce CF, Urdaneta ER, Patel MK, Franklin KB, et al. Randomized, placebo-controlled study of cetirizine and loratadine in children with seasonal allergic rhinitis. Allergy Asthma Proc 2017;38:222-30
11. Gillman SA, Blatter M, Condemi JJ, Collins M, Olufade AO, Leidy NK, et al. The health-related quality of life effects of once-daily cetirizine HCl syrup in children with seasonal allergic rhinitis. Clin Pediatr 2002;41:687-96
12. Noonan MJ, Raphael GD, Nayak A, Greos L, Olufade AO, Leidy, et al. The health-related quality of life effects of once-daily cetirizine HCl in patients with seasonal allergic rhinitis: a randomized, double-blind, placebo-controlled trial. Clin Exp Allergy 2003;33:351-8
13. Jares EJ, Badellino HA, Ensina LF. Registries as useful tools in characterization of allergic manifestations. Curr Opin Allergy Clin Immunol. 2016;16:250-6
14. Karatzas K, Katsifarakis N, Riga M, Werchan B, Werchan M, Berger U, et al. New European Academy of Allergy and Clinical Immunology Definition on Pollen Season Mirrors Symptom Load for Grass and Birch Pollen-Induced Allergic Rhinitis. Allergy 2018;73:1851-9
15. Juniper EF, Guyatt GH, Feeny DH, Ferrie PJ, Griffith LE, Townsend M. Measuring quality of life in children with asthma. Qual Life Res 1996;4:35-46
16. Use of real-world evidence to support regulatory decision-making for medical devices. Guidance for industry and Food and Drug Administration staff document issued on August 31, 2017. Bethesda: US Food and Drug Administration, US Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health Center for Biologics Evaluation and Research; 2017
17. Sherman RE, Anderson SA, Dal Pan GJ, Gray GW, Gross T, Hunter NL, et al. Real-world evidence—what is it and what can it tell us? N Engl J Med 2016;375:2293-7